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OBJECTIVE — There is growing evidence that periodontitis may affect general health. This
studywasassignedtoexploretherobustnessofobservationsthatperiodontaltherapyleadstothe
improvement of glycemic control in diabetic patients.
RESEARCH DESIGN AND METHODS — A literature search (until March 2009) was
carried out using two databases (MEDLINE and the Cochrane Library) with language restriction
to English. Selection of publications was based on 1) original investigations, 2) controlled
periodontal intervention studies where the diabetic control group received no periodontal treat-
ment, and 3) study duration of 3 months.
RESULTS — Screening of the initial 639 identiﬁed studies and reference checking resulted in
ﬁve suitable articles. A total of 371 patients were included in this analysis with periodontitis as
predictor and the actual absolute change in A1C (A1C) as the outcome. The duration of
follow-upwas3–9months.Allstudiesdescribedaresearchpopulationoftype2diabeticpatients
in whom glycemic control improved after periodontal therapy compared with the control group
(rangeA1C:1.17upto0.05%).Thestudiesinameta-analysisdemonstratedaweighted
mean difference of A1C before and after therapy of 0.40% (95% CI 0.77 to 0.04%, P 
0.03) favoring periodontal intervention in type 2 diabetic patients. Nevertheless, this improve-
ment in %A1C must be interpreted with care due to limited robustness as evidenced by hetero-
geneity among studies (59.5%, P  0.04).
CONCLUSIONS — The present meta-analysis suggests that periodontal treatment leads to
an improvement of glycemic control in type 2 diabetic patients for at least 3 months.
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P
eriodontitis is a chronic multifacto-
rial infectious disease of the sup-
porting tissues of the teeth (1). It is
estimated that between 10 and 15% of
adults from 21 to 50 years of age and
about 30% of subjects 50 years of age
havesevereperiodontitis(2,3).Clinically,
patients suffer from gradual loss of tooth
attachmentinthealveolarboneleadingto
periodontal pockets, receding gums,
loose teeth, and eventually tooth exfolia-
tion, which may result in changes in di-
versity of food uptake, possibly affecting
general health (4). Often gums are red
and swollen, bleed easily, and patients
with periodontitis suffer from bad breath.
Treatment of periodontitis includes
mechanical removal of supra- and sub-
gingival bacterial plaque with scalers, cu-
rettes or ultrasonic devices (scaling and
root planing [SRP]), and intensive oral
hygiene instructions for the patient. A
close to ideal oral hygiene regimen is the
only way to prevent formation of new
dental plaque deposits and re-infection of
thesubgingivaltissues.Theroutineuseof
systemic or local antibiotics as an adjunc-
tive therapy to SRP is still controversial in
terms of improvement of clinical peri-
odontal status (5–7). Surgery regularly is
needed to reduce or eliminate deep resid-
ual periodontal lesions.
Diabetes and periodontal disease are
two chronic diseases that have long been
considered to be biologically linked. A
large amount of case reports, cross-
sectional studies, longitudinal studies,
and reviews report the adverse effects of
diabetes on the onset, progression, and
severity of periodontitis (8,9). The preva-
lence of periodontitis in diabetic subjects
isestimatedtobedoubleoreventriplethe
number in the normal population (10). It
has been suggested that hyperglycemia
and resultant advanced glycation end
product formation, which is one of the
severalpathwaysthatisthoughttoleadto
the classic microvascular and macrovas-
cular complications of diabetes, are also
involved in the pathophysiology of peri-
odontitis in diabetic subjects (8).
There is a growing body of evidence
supporting the fact that the periodontal
infection with gram-negative microor-
ganisms (11,12) adversely affects glyce-
mic control (9,13). Thus, it is now
acknowledged that due to untreated or
inadequately controlled moderate-to-
severe periodontitis, the systemic inﬂam-
matory burden may be increased. For
example, in periodontitis patients with-
out other apparent diseases, C-reactive
protein (CRP) levels are higher compared
to subjects without periodontitis (14).
Similarly, it has been suggested that a mi-
crobiological imbalance in the gut may
increase the gram-negative bacterial load,
which, through lipopolysaccharides leak-
age into the circulation, also increases the
systematic inﬂammatory burden. The in-
creased inﬂammation eventually triggers
insulin resistance (15,16).
More direct evidence regarding the
effects of periodontal disease on glycemic
control of diabetic patients comes from
intervention studies using periodontal
therapy.Sincethebeginningofthe1990s,
several studies have investigated the asso-
ciation between periodontal therapy and
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diabetic patients. For example, Iwamoto
et al. (17) showed that periodontal treat-
ment in type 2 diabetic patients is effec-
tive in improving metabolic control.
However, the latter and many other stud-
ies are uncontrolled, provide conﬂicting
data, and report short-term results (3
months). Because of the chronic nature of
the development, progression, and sever-
ity of complications in diabetic patients,
only longer-term results of periodontal
treatment are meaningful. Therefore, we
put the hypothesis forward that if peri-
odontitis is causally related to the wors-
ening of parameters of diabetic patients,
then periodontal treatment should im-
prove glycemic control.
Our aim was to perform a systematic
review of intervention studies to answer
thequestionofwhetherperiodontaltreat-
ment affects the general health of diabetic
patients by improving glycemic control
compared with no periodontal treatment
after at least 3-month follow-up.
RESEARCH DESIGN AND
METHODS
Search strategy
Two databases, MEDLINE (via PubMed)
and the entire Cochrane Library, have
been searched using free-text search
terms and the boolean operators “OR”
and“AND”:[“Periodontaldisease”ORpe-
riodontitisOR“periodontalinfection”OR
periodont*] AND [“diabetes” OR diabet*
OR diabetic* OR “diabetic patient*” OR
“diabetes patient*” OR “non insulin de-
pendent diabetes” OR niddm OR “insulin
dependentdiabetes”ORiddmOR“type1
diabetes” OR t1dm OR “type 2 diabetes”
OR t2dm] AND [therapy OR treatment
OR intervention] from January 1960 to
31 March 2009. Additional searches were
conductedinMEDLINE’sandCochrane’s
medical subject headings with: [Peri-
odontal diseases] AND [Diabetes Melli-
tus] AND [Therapeutics OR Therapy OR
Intervention studies].
In addition, the reference lists of arti-
cles, which were obtained by the elec-
tronicsearch,weresearchedmanuallyfor
relevant articles. The language of the
studies in the literature search was re-
stricted to English.
Study selection criteria
To be included in the systematic review,
studies had to meet the following criteria:
1) original investigations; 2) intervention
studies containing diabetic patients with
periodontitis receiving periodontal
treatment and diabetic patients with
periodontitis receiving no periodontal
treatment (controlled clinical trial [CCT]
orrandomizedclinicaltrial[RCT]design)
and outcomes related to metabolic con-
trol; 3) studies with a study duration of
3 months; and 4) studies conducted
within a human population.
With the help of these inclusion crite-
ria, the title and abstract of all the articles in
the electronic search were evaluated on rel-
evance. From the selected articles, the full
texts were reviewed, followed by a decision
on their eligibility for inclusion.
Methodological study quality
assessment
For RCTs and CCTs, the following pa-
rameters were investigated (standard as-
sessment form developed by the Dutch
Cochrane Centre and the Dutch Institute
forHealthcareImprovementCBO(http://
www.cochrane.nl/nl/newPage1.html): 1)
allocation concealment, 2) randomiza-
tion, 3) blindness of examiner and/or pa-
tient, and 4) loss to follow-up.
Data extraction and statistical
analysis
From all relevant studies, the main features
that were extracted were 1) characteristics
of the population (i.e., age, sex, country of
birth, extent), 2) deﬁnition of diabetes (i.e.,
type, duration, metabolic control), 3) deﬁ-
nition of periodontitis, and 4) intervention
(i.e., type, duration), study duration, out-
come, and study design.
All suitable data for a meta-analysis
were entered and analyzed with RevMan
4.2 (http://www.cc-ims.net/RevMan). A
meta-analysis was conducted for RCTs
and CCTs in which the intervention
group received SRP (with or without ad-
junctive antimicrobial therapy), and the
control group received no periodontal
therapy. The absolute difference ()i n
%A1C for baseline-end, if not reported in
the article, was calculated for the inter-
vention and the control groups by means
of the formula:
 %A1C ti  %A1C ti 1  %A1C ti 2,
where%A1Cti1isthemean%A1Cvalue
before treatment and %A1C ti 2 is the
mean %A1C after treatment. Again, if not
reported, for some studies, the variance
(and consequently SD) of  %A1C ti was
estimated as follows (18):
St i
2  St i1
2  St i2
2  2r .St i1.St i2 ,
where S ti
2 is the variance of  in %A1C
levels, S ti 1
2 is the variance of the mean
baseline %A1C values, S ti 2
2 is the vari-
anceofthemeanend%A1Cvalue,risthe
correlation between the baseline and end
values, and S ti 1 and S ti 2 are the SDs of
the baseline and end values, respectively.
We assumed r to be 0.5 as was previously
described (19).
For each meta-analysis, the weighted
mean difference (WMD) was calculated,
nested in a random-effects model with
corresponding Z statistics, P values, and
95% CIs. Also, a test for heterogeneity
was performed. For this test, the I
2 statis-
tic describes the proportion of total vari-
ation due to heterogeneity where 0%
indicates no heterogeneity and 100% in-
dicates maximal heterogeneity among the
studies included in the meta-analysis
(20). Heterogeneity indicates the robust-
nessoftheWMD.Theresultsofthemeta-
analysisarepresentedinaforestplotwith
the following indicators 1) the raw data
(means and SDs) for each arm per in-
cluded study; 2) point estimates and CIs
for the chosen effect measure, as blocks
and lines, respectively; 3) heterogeneity
statistic (I
2); 4) the total number of partic-
ipants per group; 5) the overall average
effect (WMD and Z statistics) in a ran-
dom-effectsmodel;and6)percentweight
given to each study.
RESULTS— The combined MED-
LINE (via PubMed) and the Cochrane
Central searches resulted in 639 poten-
tially eligible articles (Fig. 1). These arti-
cleswerescreenedbytitleandabstractfor
relevance. The screening resulted in 74
articlesthatqualiﬁedforfull-textreading.
After full-text reading, 40 articles were
deemedunsuitableandwerethereforeex-
cluded (supplemental Table 1A and C,
which is available in an online appendix
at http://care.diabetesjournals.org/cgi/
content/full/dc09-1378/DC1). Screening
ofthereviews(n29)(supplementalTa-
ble 1B) for unpublished data did not pro-
videanyadditionalarticles.Supplemental
Table 1C presents the excluded interven-
tion studies (n  35) and the main reason
for exclusion. Five articles (three RCTs
and two CCTs) fulﬁlled the inclusion cri-
teria and were processed for data extrac-
tion (Table 1) (21–25).
General characteristics
From the ﬁve included studies, two were
performed in North America (the U.S.)
(21,25), two were performed in Asia
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was performed in the Middle East (Tur-
key) (23). The study duration ranged
from 3 to 9 months. All studies described
a study population having type 2 diabetes
and suffering from periodontitis. In total,
199 patients (range 22–82 patients per
study)wereintheinterventiongroupand
183 patients (range 17–83 patients per
study) were in the control group. The
mean age per study ranged from 56 to 62
years for the intervention group and from
53 to 67 years for the control group. In
addition, the baseline A1C levels per
study ranged from 7.2 to 9.9% for the
intervention group, whereas the baseline
A1C levels for the control group ranged
from 6.9 to 10.2%.
All subjects in the intervention group
received SRP with (21,22,24) or without
(23,25) local or systemic administration
of antibiotics, whereas no subject of the
control group received any form of peri-
odontal intervention.
Periodontal intervention and A1C
All studies reported absolute changes ()
inA1Casparameterofmetaboliccontrol.
Fouroftheﬁvestudiesreportedmeandif-
ferences between baseline and end of trial
with or without SDs (21,23–25). One
study(22)reportedchangesofA1Clevels
graphically; the mean values and SDs
were obtained through e-mail communi-
cation with the authors. Two of the ﬁve
studies showed a signiﬁcant improve-
ment in metabolic control after periodon-
tal treatment as measured by a signiﬁcant
decrease in A1C levels compared with that
in the untreated control group (I
ntervention-
Control [I-C] 1.17% [(23)], I-C
1.10% [(25)]). Katagiri et al. (22),
Jones et al. (21), and Promsudthi et al.
(24) also showed a decrease in A1C levels
after periodontal therapy (I-C 0.05%,
I-C 0.16%, and I-C 0.31%, re-
spectively); however, these decreases
were reported to be not signiﬁcant. A
multiple regression analysis in the study
by Katagiri et al. (22) for signiﬁcant vari-
ables associated with changes of A1C lev-
els between baseline and 6 months
showed that the A1C decrease correlated
with decreases in high-sensitivity CRP
(hs-CRP) levels after periodontal treat-
ment (P  0.03) (22). Based on this anal-
ysis, Katagiri et al. (22) divided the
intervention group into CRP-decreased
and CRP-unchanged groups. This suba-
nalysis showed that A1C levels decreased
signiﬁcantly in the CRP-decreased group
compared with baseline levels, but not in
the CRP-unchanged group.
Periodontal intervention and other
parameters of glycemic control
Threestudiesalsoreportedchangeinfast-
ing plasma glucose (FPG) as parameter of
metabolic control, and two studies
showed a nonsigniﬁcant decrease in FPG
after periodontal treatment compared
with that in the control group (I-C
5.18 mg/dl [23], I-C 3.83 mg/dl
[24]).Notably,Katagirietal.(22)showed
a nonsigniﬁcant deterioration of meta-
bolic control as reﬂected by a nonsigniﬁ-
cant increase in FPG after periodontal
treatment compared with that in the con-
trol group (I-C 22 mg/dl). In addition,
Kiran et al. (23) showed a signiﬁcant de-
crease of 2-h postprandial glucose (PPG)
levelsafterperiodontaltherapycompared
with baseline levels of the treatment
group (Iend of trial-Ibaseline 23.6 mg/dl,
P  0.027). However, compared with
that in the control group, the decrease in
2-h PPG levels was not signiﬁcant (I-C
25.1 mg/dl, P  0.067).
Meta-analysis
The effect of periodontal treatment on
A1C levels (ﬁve studies) and FPG levels
(threestudies)couldbeanalyzedfromthe
available intervention studies (Fig. 2A
and B). The range of A1C mean differ-
ences between baseline and end for the
treatment groups was 1.90 to 0.14%,
whereas the untreated individuals
showed a range of 0.80 to 0.31%. The
WMD of A1C mean differences baseline
to end between treatment groups and
control groups was 0.40% (95% CI
0.04 to 0.77%) (test of the overall ef-
fect,P0.03).Theheterogeneity(I
2)be-
Figure 1—Flow chart outlining the search strategy and results along various steps.
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0.04) (Fig. 2A).
The range of FPG mean differences
between baseline and end for the treat-
ment groups was 3.63 to 19.00 mg/dl,
whereastheuntreatedindividualsshoweda
range of 3.00 to 1.22 mg/dl. The WMD
of mean FPG differences baseline-end be-
tween treatment groups and control
groups was 2.30 mg/dl (95% CI 13.64
to 18.24 mg/dl) (test of the overall effect,
P0.78).Theheterogeneity(I
2)between
the three studies was 23.7% (P  0.27)
(Fig. 2B).
CONCLUSIONS— The current re-
view provides the most accurate reﬂec-
tion of available literature to date to
answerthequestionofwhetherperiodon-
tal treatment affects the general health of
type 2 diabetic patients by improving gly-
cemic control compared to no periodon-
tal treatment after at least 3-month
follow-up. Although previous systematic
reviews on this topic (5,26) were con-
ducted, we believe that the current inclu-
sion criteria of available studies result in a
better understanding of the effect of peri-
odontal treatment on diabetic patients for
the following reasons: 1) We included
only studies with at least 3-month follow-
up. A1C is a reﬂection of the mean blood
glucose concentration over the preceding
1–3 months and a difference over a
shorter period may be clinically less rele-
vant (13). 2) We only used controlled
studies in our analysis in which the con-
trol group with type 2 diabetes received
noperiodontaltreatmenttoovercomethe
problem of a possible Hawthorne effect
(27). 3) The calculation of WMD is the
most suitable parameter for a proper meta-
analysis(28)sinceback-transformationof a
standardizedmeandifference(5)willlead
to an overestimation of the total effect of
periodontal therapy.
Thus, we conclude from the current
systematic review, based on strict inclu-
sion criteria of literature, that periodontal
therapy for type 2 diabetic patients with
periodontitis is favorable and can reduce
A1C levels on average by 0.40% more
than in nonintervention control subjects.
Changes in (blood) levels of
markers, which reﬂect the metabolic
regulation of diabetes
Although only two of the ﬁve studies
showed an improvement of metabolic
control after periodontal treatment
(23,25), the results of all studies com-
bined in our meta-analysis suggest that
periodontal treatment results in an abso-
lute decrease of A1C of 0.40% compared
with no periodontal treatment in type 2
diabetic patients. This decrease of A1C is
also clinically relevant since any decrease
of A1C will result in less diabetic compli-
cations (29,30).
Interestingly, the improvement in
glucose metabolism, as evidenced by the
reduction of %A1C, was not seen in FPG
levels (Fig. 2B). However, FPG levels re-
ﬂect the metabolic control at one time
point and one moment of the day,
whereas A1C reﬂects glucose metabolism
over the preceding 1–3 months; this is
also true for PPG levels.
The results of our A1C meta-analysis
need to be viewed with caution for four
mainreasons:1)Thelackofrobustnessas
revealed by the signiﬁcant heterogeneity.
Inadequate attention to heterogeneity
may result in misinterpretation of the re-
sults (31). For example, there is only mi-
nor overlap of the CIs between the Kiran
et al. (23) and Katagiri et al. (22) trials,
suggestingthatthesestudiesarelesscom-
parable; differences in ethnicity and
lifestyle factors may be a possible expla-
nation. 2) The small number of studies
(n  5) with relative small study groups.
There is a lack of large randomized con-
trolled intervention trials in type 2 dia-
betic patients. 3) The shortcomings in
study design of several studies. Two stud-
ies used groups with selection bias by
placing treatment avoiders in the control
group (24,25). Two other studies used
metabolically controlled diabetic patients
asdeterminedbya%A1Cof7,possibly
affecting improvement of metabolic con-
trol after periodontal treatment (22,23).
Furthermore, the use of systemic or local
antibiotics as an adjunctive therapy to ba-
sic periodontal treatment is possibly an-
other factor of study design that may
inﬂuence the outcome. It is interesting to
notethattheonlytwostudiesinourmeta-
analysis that showed a signiﬁcant de-
crease in A1C levels after periodontal
treatmentdidnotuseantibioticsasanad-
junctive therapy (23,25), whereas the
other studies did use antibiotics. The use
ofantibioticsisstillcontroversialwhether
it is beneﬁcial in terms of improvement of
clinical periodontal status (5–7) or glyce-
miccontrol(32,33).Itisclearthatfurther
trials speciﬁcally addressing this adjunc-
tive form of periodontal therapy are
needed. 4) The lack of an instrument to
quantify periodontal inﬂammation for all
studies. Inﬂammation is associated with
the onset and progression of diabetes
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odontal inﬂammation and possibly also
quantifyingthepathogenicbacterialload,
together with the improvement of meta-
bolic control, will give us more insight
into the relation between periodontitis
anddiabetes.Mostlikely,treatmentofthe
generalized severe form of periodontitis
will be more beneﬁcial in terms of glyce-
miccontrolofdiabeticpatientsthantreat-
ment of the localized moderate form of
periodontitis. Recently, a new tool has
beendevelopedtoquantifytheinﬂamma-
tory burden of periodontitis (34) and
showed that the amount of periodontal
inﬂammationwasrelatedtoA1Cvaluesof
diabeticpatientsinadose-respondedway
(35). Regarding the relation between sys-
temic inﬂammatory burden and diabetes,
one study (22) reported the effect of peri-
odontaltreatmentonhs-CRPbloodlevels
in diabetic patients. The authors revealed
inamultipleregressionanalysisofallsub-
jects that hs-CRP levels at 1 month after
periodontal treatment correlated signiﬁ-
cantly with the reduction of A1C at 6
months after periodontal treatment. It
suggests that change in hs-CRP level is a
factor related to the change in A1C level.
Ithasbeenreportedthatinﬂammationdi-
rectly induces insulin resistance in type 2
diabetic patients (36). Some other studies
reported signiﬁcant decrease of plasma
levels of several inﬂammation markers
(reactive oxygen species, interleukin [IL]-
1
, IL-6) compared with baseline levels
after periodontal therapy (37,38). Some
of these inﬂammatory cytokines (tumor
necrosis factor [TNF]-, IL-6, and IL-1)
have been shown to have important ef-
fects on glucose and lipid metabolism by
antagonizing the insulin action (IL-6 and
IL-1) and/or interfering with lipid metab-
olism (TNF-) (9,15,36,39). For exam-
ple, Iwamoto et al. (17) already suggested
that periodontal treatment in type 2 dia-
betic patients is effective in improving
metabolic control possibly through re-
ducedTNF-levelsandimprovedinsulin
resistance. However, this study did not
useanuntreatedcontrolgroupandthere-
fore was not included in the current sys-
tematic review.
We have shown that periodontal
treatment leads to improvement of the
general health of type 2 diabetic patients
by affecting the metabolic control: after
periodontal treatment, A1C can be signif-
icantly reduced by absolute 0.40% based
on RCTs and CCTs with at least 3-month
follow-up. However, more evidence is
needed as is reﬂected by a wide CI. More
homogeneous evidence is needed as is re-
ﬂected by a signiﬁcant heterogeneity
(0.59%) among the studies. We propose
further trials to be initiated as follows
(40):
● A large single-blind randomized con-
trolled study of diabetic patients with
moderate or severe periodontitis.
● The treatment group to receive basic
periodontal treatment (oral hygiene
instruction and SRP), whereas the
control group not to receive any form
of periodontal treatment.
● Follow-up period 6 months.
● Sample size is large enough to analyze
patients with moderate and severe pe-
riodontitis separately.
● Outcome:
● Changein(plasma)markersofglyce-
mic control.
● Change in the amount of periodontal
inﬂammation.
● Change in (plasma) markers of sys-
temic inﬂammation.
ADDENDUM— No new studies ac-
cording to the inclusion criteria of this
articlehaveappearedintheliteratureasof
the time of the production of this article
(November 2009).
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